Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischemia?

International Angiology

Volumn 25, Issue 4, 2006, Pages 370-377

  Bertz, L ^a   Barani, J ^a   Gottsater A ^a   Nilsson, P M ^a   Mattiasson, I ^a   Lindblad, Bengt ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

CD40L; Diabetes mellitus; Inflammatory markers; Limb ischemia; Neopterin; Tumor necrosis factor alfa

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; CREATININE; ENDOTHELIN 1; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; ISOPROSTANE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOPTERIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GANGRENE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; LIMB ISCHEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; SKIN ULCER;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CRITICAL ILLNESS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKIN-6; ISCHEMIA; LEG; MALE;

EID: 33847673520     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
2. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003;25 Suppl B:B4-31.
3. Samra SS, Walwaikar PP, Morye VK, Gawde AG. Accelerated atherosclerosis. J Indian Med Assoc 2002;100:516-21.
4. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107: 2664-9.
5. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1979-1993. Diabetes Care 1998;21:1138-45.
6. Crawford JS, Cotran RS. The pancreas. In: Cotran RS, Kumar V, Collins T, editors. Robbins pathologic basis of disease. Philadelphia, USA: W. B. Saunders Company; 1999.p.902-29.
7. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.
8. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003;91 Suppl:3A-6A.
9. Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999;145:51-60.
10. Nilsson P, Berglund G. Prevention of cardiovascular disease and diabetes: lessons from the Malmo Preventive Project. J Intern Med 2000;248:455-62.
11. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115 Suppl 8A:99S-106S.
12. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003;96:793-807.
13. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92:10i-18i.
14. Barani J, Noilsson JA, Mattiasson I, Lindblad B, Gottsäter A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 2005;42:75-80.
15. Dormandy JA, Rutherford RB, TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:S170.
16. Virkunnen J, Heikkinen M, Lepäntalo M, Metsanoja R, Salenius JP; Finnvasc Study Group. Diabetes as an independent risk factor for early postoperative complications in crtitcal limb ischemia. J Vasc Surg 2004;40:761-7.
17. da Silva AF, Desgranges P, Holdsworth J, Harris PL, McCollum P, Jones SM et al. The management and outcome of critical limb ischaemia in diabetic patients: results of a national survey. Audit Committee of the Vascular Surgical Society of Great Britain and Ireland. Diabet Med 1996;13:726-8.
18. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-22.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
20. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002;144:233-8.
21. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003;108:2323-8.
22. Tanaka T, Nakamura Y, Nasuno A, Mezaki T, Higuchi K, Fukunaga H et al. Plasma concentrations of monocyte chemoattractant protein 1 (MCP-1) and neopterin in the coronary circulation of patients with coronary artery disease. Circ J 2004;68:114-20.
23. Buchner K, Henn V, Grafe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol 2003;201:288-95.
24. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004;93:6-9.